About Acceleron Pharma
Acceleron Pharma is a company based in Cambridge (United States) founded in 2004 was acquired by Merck in September 2021. Acceleron Pharma has raised $137.67 million across 9 funding rounds from investors including Merck, Bessemer Venture Partners and Alkermes. Acceleron Pharma offers products and services including Vaccines and Medicines.
Products & Services of Acceleron Pharma
Acceleron Pharma offers a comprehensive portfolio of products and services, including Vaccines and Medicines.
Develops vaccines for infectious diseases and prevention.
Provides treatments for oncology and other disorders.
Funding Insights of Acceleron Pharma
Acceleron Pharma has successfully raised a total of $137.67M across 9 strategic funding rounds. The most recent funding activity was a Post-IPO round of $30 million completed in May 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $137.67M
- Total Rounds 9
- Last Round Post-IPO — $30M
- First Round $25M
(Feb 2004)
- Investors Count 11
All 9 funding rounds of Acceleron Pharma with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May 2017 | $30M | Post-IPO | – | – | – |
| Sep 2013 | $10M | Post-IPO | – | – | – |
| Jan 2012 | $30.47M | Series D | – | Celgene, Alkermes | |
| Jan 2011 | $1.5M | Grant | – | – | – |
| Jul 2010 | $10.25M | Series D | – | – | – |
| Dec 2009 | $10.95M | Series D | – | – | – |
| Oct 2007 | $31M | Series C | – | Bessemer Venture Partners | |
| Aug 2006 | $30M | Series B | – | – | |
| Feb 2004 | $25M | Series A | – | – |
12 investors in total: 12 institutional.
Investors in Acceleron Pharma
Acceleron Pharma has secured backing from 12 investors, including institutional and venture fund investors. Prominent investors backing the company include Merck, Bessemer Venture Partners and Alkermes.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
VC firm making investment in early stage startups in the US | – | atvcapital.com | Menlo Park, United States | |
Seed and early-stage venture capital is provided to US companies. | – | avalon-ventures.com | Cambridge, United States | |
Venture capital investments and support for entrepreneurs in technology and innovation sectors. | 1911 | bvp.com | Redwood City, United States | |
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields. | 1989 | orbimed.com | New York, United States | |
Investment management in biotech, technology, energy, shipping, financials, and litigation sectors. | 2003 | qvt.com | - | |
VC firm investing in the US | – | shv.com | Palo Alto, United States | |
Venture capital firm focused on tech sectors | – | venrock.com | Palo Alto, United States | |
Life sciences-focused venture capital firm | 1999 | flagshippioneering.com | Cambridge, United States | |
US focused venture capital firm | – | polarispartners.com | Boston, United States | |
Therapies for cancer and inflammatory diseases are developed. | 1986 | celgene.com | Summit, United States |
Investor details for Acceleron Pharma
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Acceleron Pharma
1248 people are tracked at Acceleron Pharma (845 in leadership, 12 in board & advisors, 391 in team).
| Name | Role | Group |
|---|---|---|
Jacob Bordens | Senior Director, Enterprise Architecture | Leadership |
Kelley Brna | Vice President Operations | Leadership |
Robert Tynebor | Director | Leadership |
Jerry Timmons | Retired Associate Director Of Operations | Leadership |
Sebastian S. | Director | Leadership |
Dave Williams | EVP, Chief Information & Digital Officer | Leadership |
Hardik Chandasana | Director, Quantitative Pharmacology And Pharmacometrics | Leadership |
My Mansueto | Director | Leadership |
Edina Avdic | Associate Director-regulatory Affairs-global Labeling | Leadership |
Manshi Patel | Associate Director- Global Microbial Quality Sterility Assurance | Leadership |
Sany Hoxha | Director, Oncology Translational Science And Clinical Biomarkers | Leadership |
Ashley Wivel | Vice President, Head Of Clinical Safety And Risk Management | Leadership |
Naveed Shaik | Director, Quantitative Pharmacology And Pharmacometrics | Leadership |
Allison Shaner | Chief Of Staff, HR Manufacturing | Leadership |
Brandon Koffel | Associate Director Discovery Sourcing & Procurement - Global Clinical Supply & Analytical Labs | Leadership |
Andrea Lorena Buitrago Lozano | Associate Director, Lead Study Manager | Leadership |
Aatosh Chauhan | Executive Director, External Manufacturing Strategy & Operations At Merck | Leadership |
Renata Eiras | Executive Director, Distinguished Scientist, PDT Lead | Leadership |
Gina M. Gualtiere Mshs | Associate Director Clinical Quality Operations | Leadership |
Brendan McLaughlin | Associate Director, US Oncology Marketing, Campaign Development Lead | Leadership |
1228 more people are available in the full profile.
Complete people profiles for Acceleron Pharma
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Acceleron Pharma
5 dated milestones of Acceleron Pharma across 17 years, from founding to its latest funding, stage changes and deals.
- Founded Acceleron Pharma is founded.
- Funding First funding round of $25.0M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $30.0M.
- Exit Acquired by Merck.
Web traffic of Acceleron Pharma
Websites that share an audience with Acceleron Pharma (acceleronpharma.com).
Websites whose visitors overlap most with Acceleron Pharma. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| onyx-pharm.com | 100% | – | – | View details | |
| ipsen.com | 100% | 112.9K | #336,868 | View details | |
| themedicinescompany.com | 100% | – | – | View details | |
| vrtx.com | 100% | 342.2K | #151,023 | View details | |
| exelixis.com | 100% | 39.1K | #1,001,350 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 21 similar websites and full traffic analytics for Acceleron Pharma
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 21 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Latest news on Acceleron Pharma
Complete news archive for Acceleron Pharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Acceleron Pharma
10 companies that operate in the same segment as Acceleron Pharma (Pharmaceuticals & Distribution), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Pharmaceutical products are manufactured and marketed worldwide. | 1891 | Kenilworth, Warwickshire, United Kingdom | – | USD 64.93 B | 781 | |
Therapeutics for neurology, oncology, rare, and endocrinology diseases are developed. | 2014 | New York, New York, United States | USD 1.3 B | USD 8.26 M | 750 | |
Developer of pharmaceutical products for treating multiple diseases | 1980 | Thousand Oaks, California, United States | – | USD 33.23 B | 28,000 | |
Biopharmaceutical research and drug development are conducted globally by AbbVie. | 2012 | Chicago, Illinois, United States | – | USD 61.16 B | 55,000 | |
Traditional pharmaceutical medicines are developed for multiple health fields. | 1876 | United States | – | USD 65.18 B | 47,000 | |
Developer of medicines to treat HIV/AIDS, liver diseases, cancer & others | 1987 | Foster City, California, United States | – | USD 29.45 B | 17,600 | |
Novel therapeutics are discovered using an AI-enabled drug platform. | 2013 | New York, New York, United States | USD 456.66 M | USD 74.68 M | – | |
Treatments for anemia and fibrosis by exploiting connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology. | 1993 | San Francisco, California, United States | USD 215.5 M | USD 29.62 M | 225 | |
Developer of medical devices, generic pharmaceuticals, and nutrition products | 1888 | Libertyville, Illinois, United States | – | USD 44.33 B | 3,710 | |
Medicines and health products are retailed through pharmacy outlets. | 2006 | Hyderabad, Telangana, India | USD 268.78 M | USD 734.57 M | 25,010 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Acceleron Pharma
Acceleron Pharma was founded in 2004.
Acceleron Pharma is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Acceleron Pharma is a funded company, having raised a total of $137.67M across 9 funding rounds to date. The company's 1st funding round was a Series A of $25M, raised on Feb 2004.
Acceleron Pharma is a developer of protein therapeutics to treat cancer and rare blood disorders. The company is developing luspatercept and sotatercept therapeutic candidates to treat anemia and associated complications in patients with ß-thalassemia and myelodysplastic syndromes. The sotatercept therapeutic candidate is also used to increase bone mineral density, and to treat the final stage of chronic kidney disease and end-stage renal disease. It is also developing a dalantercept therapeutic candidate to treat renal cell carcinoma, hepatocellular carcinoma, and ACE-083 that is in Phase 1 clinical trial used to promote muscle growth and function in specific treated muscle groups.
Acceleron Pharma offers Vaccines and Medicines.
Acceleron Pharma has 12 investors. Key investors include Merck, Bessemer Venture Partners, Alkermes, Flagship Pioneering, and Orbimed.
Acceleron Pharma operates through Merck & Co., Inc..
Yes. Acceleron Pharma was acquired by Merck in September 2021.